| 注册
首页|期刊导航|中国临床药理学杂志|达格列净对冠心病合并2型糖尿病患者心外膜脂肪衰减值的影响

达格列净对冠心病合并2型糖尿病患者心外膜脂肪衰减值的影响

刘美 冯雪茹 刘梅林

中国临床药理学杂志2024,Vol.40Issue(9):1243-1247,5.
中国临床药理学杂志2024,Vol.40Issue(9):1243-1247,5.DOI:10.13699/j.cnki.1001-6821.2024.09.001

达格列净对冠心病合并2型糖尿病患者心外膜脂肪衰减值的影响

Effect of dapagliflozin treatment on epicardial fat attenuation in patients with coronary heart disease and type 2 diabetes mellitus

刘美 1冯雪茹 1刘梅林1

作者信息

  • 1. 北京大学第一医院老年病内科,北京 100034
  • 折叠

摘要

Abstract

Objective To analyze the effect of dapagliflozin on epicardial fat attenuation(EFat)in patients with coronary heart disease and type 2 diabetes.Methods The patients with coronary heart disease and type 2 diabetes in our hospital were retrospectively collected.The patients were grouped into treatment group and control group.The treatment group was newly treated with dapagliflozin on the basis of the original treatment.The control group maintained the original antidiabetic drugs without using dapagliflozin.After median follow-up of thirteen months,the clinical characteristics,including body mass index(BMI),fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),triglycerides,total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and EFat between the two groups were compared.Results A total of 235 patients were collected,of which 205 cases completed follow-up.There were 111 cases in the treatment group and 94 cases in the control group.The BMI,FBG and HbA1c of patients in the treatment group significantly decreased compared to those before therapy,while HDL-C significantly increased.The EFat of patients in the treatment group significantly decreased compared to baseline[(-96.48±14.71)HU vs(-88.59±10.60)HU,P<0.05].Pearson correlation analysis showed a negative correlation between changes in EFat and changes in HDL-C in patients in the treatment group(r=-0.188,P<0.05).Conclusion Dapagliflozin can reduce the epicardial fat attenuation in patients with coronary heart disease and type 2 diabetes.

关键词

钠-葡萄糖共转运蛋白2抑制剂/达格列净/冠心病/2型糖尿病/心外膜脂肪

Key words

sodium-glucose cotransporter 2 inhibitor/dapagliflozin/coronary heart disease/type 2 diabetes mellitus/epicardial adipose tissue

分类

医药卫生

引用本文复制引用

刘美,冯雪茹,刘梅林..达格列净对冠心病合并2型糖尿病患者心外膜脂肪衰减值的影响[J].中国临床药理学杂志,2024,40(9):1243-1247,5.

基金项目

北京大学第一医院科研种子基金资助项目(2020SF22) (2020SF22)

北大百度基金资助项目(2019BD019) (2019BD019)

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文